Tabelecleucel (Ebvallo) FDA Update: Approval Delayed Despite Positive Phase 3 Data - OncoDaily Tabelecleucel FDA approval delayed by CRL due to manufacturing issues, not clinical data. ALLELE trial supports its use for EBV+ PTLD post-transplant patients.

Tabelecleucel (Ebvallo) FDA Update: Approval Delayed Despite Positive Phase 3 Data
@fda.gov

oncodaily.com/oncolibrary/...

#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #Tabelecleucel #Ebvallo #FDA